Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery

Recruiting now · Phase 2

Conditions studied: Head and Neck Cancer

In brief

Assess the sensitivity of real-time near-infrared fluorescence imaging to detect microscopic residual disease in the operating room after a complete macroscopic surgical resection of head and neck cancers

Key facts

Study ID

NCT04842162

Run by

Gustave Roussy, Cancer Campus, Grand Paris

People needed

65

Starts

2020-12-15

Expected to finish

2026-11-01

Last updated by the study team

2025-11-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female 18 years of age or older
• ECOG performance status 0-2
• Histological confirmation of squamous cell carcinoma
• Locating the primary tumour in the oral cavity or oropharynx
• Disease operable for complete resection
• Serum or urinary pregnancy test (as per centre practices) negative within 14 days prior to systemic indocyanin green injection (pre-operative visit), for women of childbearing age
• Patient information and signed free and informed consent
• Patient affiliated with a social security scheme or beneficiary of a similar scheme.
• The patient must understand, sign and date the consent form prior to any protocol-specific procedures. The patient must be able and willing to comply with the study visits and procedures described in the protocol

You may not qualify if…

• Severe medical co-morbidities or contraindications to surgery
• Primary tumour not operable
• History of head and neck cancer in the past 5 years
• History of radiation for head and neck cancer
• Metastatic cancer
• Tumours with necrosis ranges in pre-operative imaging
• History of invasive cancer unless there has been no recurrence for more than 5 years with an exception for non-melanoma skin cancers.
• Pregnant or nursing woman
• Allergy or hypersensitivity to the product being administered (its active substance or other ingredients), iodized products or crustaceans.
• Hyperthyroidism, thyroid adenoma, unifocal, multifocal or multinodular goiter of autoimmune origin.
• Documented coronary artery disease
• Advanced renal failure (creatinine > 1.5mg/dL).
• Within 2 weeks prior to inclusion, concomitant medication that reduces or increases extinction of GI (i.e. anticonvulsants, haloperidol and Heparin).
• Patient under guardianship or curatorship or deprived of liberty by judicial or administrative decision or patient unable to give consent.
• Patients unable to undergo medical follow-up of the trial

Where it is running

• Institut Jules Bordet — Anderlecht, Belgium (enrolling)
• Gustave Roussy — Villejuif, Val De Marne, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.